Plus Therapeutics Completes 5th Dose Escalation Cohort & Expands Sites in the ReSPECT Clinical Trial from rhenium re Watch Video
Preview(s):
Gallery
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Description: Austin, Texas, July 28, 2020 -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”) today announced the successful completion of the fifth cohort of the ReSPECT Clinical Trial and expansion to a second clinical trial site, the UT Southwestern Medical Center in Dallas.nnThe Phase 1 ReSPECT Clinical Trial is intended to assess the safety, tolerability, and distribution of a novel radiotherapy, Rhenium NanoLiposomes (RNL™), in adults with recurrent glioblastoma (GBM) after standard surgica
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)